ORMP

$4.02+0.50%visit website

ORAMED PHARMACEUTICALS INC.

Market Cap

$167M

Live price × SEC shares (Aug 10, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

1.29

60mo monthly vs SPY

P/E (TTM)

1.0

TTM to Jun 2026 · diluted EPS

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

0.5

Mkt cap / shareholders' equity

Flagged input, hover for details

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	0.00	0.00
Cost of revenue	0.00	0.00
Gross profit	0.00	0.00
Research & development	1,153	1,988	1,594	0	4,735
Operating income	(2,427)	(5,672)	(3,659)	(2,766)	(14,524)
Pretax income	59,451	9,797	49,440	101,587	220,275
Income tax	11,062	(212)	11,130	23,431	45,411
Net income	48,395	10,009	38,310	78,156	174,870
EPS (basic) ($)	1.16		0.94	1.90	4.24
EPS (diluted) ($)	1.13		0.91	1.84	4.13
Weighted avg. shares (basic)	41,756		40,774	41,040
Weighted avg. shares (diluted)	42,775		41,970	42,501

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 10, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 62 more quarters, back to Nov 2010, with Tormere Pro.

Corporate Events (8-K)

10 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Sep 17, 2026 accepted 7:37 PM ET	5.07Shareholder vote	Document SEC ↗
Jun 30, 2026 accepted 8:19 PM ET	5.03Bylaws / fiscal year8.01Other events	Document SEC ↗
Mar 31, 2026 accepted 8:20 PM ET	1.01Material agreement2.01Acquisition / disposition	Document SEC ↗
Feb 20, 2026 accepted 9:26 PM ET	1.01Material agreement	Document SEC ↗
Jan 14, 2026 accepted 9:31 PM ET	1.01Material agreement8.01Other events	Document SEC ↗
Jan 7, 2026 accepted 1:56 PM ET	8.01Other events	Document SEC ↗
Dec 31, 2025 accepted 9:30 PM ET	5.02Officer / director change	Document SEC ↗
Dec 31, 2025 accepted 1:51 AM ET	8.01Other events	Document SEC ↗
Nov 17, 2025 accepted 2:05 PM ET	2.02Earnings release	Document SEC ↗
Nov 17, 2025 accepted 1:50 PM ET	1.01Material agreement3.03Holder rights modified	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

51%

W/W +1.7pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

1.61x

Avg Daily Selling (90d)

556 sh/day

Baseline Daily Selling

859 sh/day

Unique Sellers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-10-01	2026-10-02	Gabay Avraham	Chief Financial Officer	Sale	20.0K	$4.51	$90K	861.1K	View
2026-10-01	2026-10-02	Hexter Joshua	COO & CBO	Sale	30.0K	$4.51	$135K	1.33M	View
2026-07-01	2026-07-02	Gabay Avraham	Chief Financial Officer	Sale	73.4K	$4.51	$331K	671.8K	View
2026-07-01	2026-07-02	Hexter Joshua	COO & CBO	Sale	137.0K	$4.46	$611K	1.02M	View

Recent News

Oramed Pharmaceuticals Inc. (ORMP) Peer Comparison – Compare with Others

Value Research · 2026-11-04

ORMP Nov 2026 5.000 call (ORMP261120C00005000) stock price, news, quote and history

Yahoo Finance UK · 2026-11-01

Oramed Pharmaceuticals Inc. (ORMP) Seasonal Returns Chart

Yahoo! Finance Canada · 2026-10-30

Oramed Pharmaceuticals Inc. Estimates – NASDAQ:ORMP

TradingView · 2026-10-23

Oramed Pharmaceuticals CFO Avraham Gabay sells $90,200 in stock

Investing.com · 2026-10-02

An officer proposes selling 20,000 Oramed (ORMP) shares under a preset trading plan.

Stock Titan · 2026-10-01

Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy

Yahoo Finance · 2026-09-08

ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness

Yahoo Finance · 2026-08-28

Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee

Yahoo Finance · 2026-08-17

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

Yahoo Finance · 2026-06-25

ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community

Yahoo Finance · 2026-06-18

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

PR Newswire · 2026-06-17

ORMP: Strategically Acquiring Interests in Medtech & Technology Companies

Yahoo Finance · 2026-06-08

Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction

Seeking Alpha · 2026-05-22

Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors

Yahoo Finance · 2026-04-14

Informational purposes only, not investment advice.

ORMP

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

ORAMED PHARMACEUTICALS INC. (ORMP)

Reporting Insiders

Factor Profile

Corporate Events (8-K)

Date	Insider	Type	Shares	Value
2026-10-01	Gabay Avraham	S	20,000	$90,200
2026-10-01	Hexter Joshua	S	30,000	$135,330
2026-07-01	Gabay Avraham	S	73,360	$330,743.56
2026-07-01	Hexter Joshua	S	137,000	$611,431